Efficacy and Safety of Danirixin (GSK1325756) Co-administered With Standard-of-Care Antiviral (Oseltamivir): A Phase 2b, Global, Randomized Study of Adults Hospitalized With Influenza

BACKGROUND: Excessive neutrophil migration has been correlated with influenza symptom severity. Danirixin (GSK1325756), a selective and reversible antagonist of C-X-C chemokine receptor 2, decreases neutrophil activation and transmigration to areas of inflammation. This study evaluated the efficacy...

Descripción completa

Detalles Bibliográficos
Autores principales: Madan, Anuradha, Chen, Shuguang, Yates, Phillip, Washburn, Michael L, Roberts, Grace, Peat, Andrew J, Tao, Yu, Parry, Michael F, Barnum, Otis, McClain, Micah T, Roy-Ghanta, Sumita
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Major Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6483311/
https://www.ncbi.nlm.nih.gov/pubmed/31041358
http://dx.doi.org/10.1093/ofid/ofz163

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6483311/
https://www.ncbi.nlm.nih.gov/pubmed/31041358
http://dx.doi.org/10.1093/ofid/ofz163

Ejemplares similares